BG64390B1 - Карбоцикличен нуклеозиден хемисулфат и неговото използване при лечението на вирусни инфекции - Google Patents

Карбоцикличен нуклеозиден хемисулфат и неговото използване при лечението на вирусни инфекции Download PDF

Info

Publication number: BG64390B1
Authority: BG; Bulgaria
Prior art keywords: salt; methanol; cyclopropylamino; purin; amino
Prior art date: 1997-05-17

Application number

BG103959A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103959A (en

Inventor

Alastair BRODIE

Martin Jones

John SEAGER

Christopher Wallis

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-17

Filing date

1999-12-07

Publication date

2004-12-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10812407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64390(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-07 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2000-12-29 Publication of BG103959A publication Critical patent/BG103959A/xx

2004-12-30 Publication of BG64390B1 publication Critical patent/BG64390B1/bg

Links

238000011282 treatment Methods 0.000 title claims abstract description 12
208000036142 Viral infection Diseases 0.000 title claims abstract description 7
230000009385 viral infection Effects 0.000 title claims abstract description 7
-1 Carbocyclic nucleoside Chemical class 0.000 title claims description 5
239000002777 nucleoside Substances 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 68
150000001875 compounds Chemical class 0.000 claims abstract description 60
238000002360 preparation method Methods 0.000 claims abstract description 25
238000000034 method Methods 0.000 claims abstract description 24
239000003814 drug Substances 0.000 claims abstract description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 7
239000012453 solvate Substances 0.000 claims abstract description 5
239000000203 mixture Substances 0.000 claims description 69
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 22
125000006317 cyclopropyl amino group Chemical group 0.000 claims description 12
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 9
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
208000015181 infectious disease Diseases 0.000 claims description 8
238000002156 mixing Methods 0.000 claims description 7
150000003873 salicylate salts Chemical class 0.000 claims description 5
229940124597 therapeutic agent Drugs 0.000 claims description 5
150000001991 dicarboxylic acids Chemical class 0.000 claims description 4
230000003287 optical effect Effects 0.000 claims description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 3
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
239000007963 capsule composition Substances 0.000 claims description 2
229940125758 compound 15 Drugs 0.000 claims description 2
229940047124 interferons Drugs 0.000 claims description 2
239000012669 liquid formulation Substances 0.000 claims description 2
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 2
239000007916 tablet composition Substances 0.000 claims description 2
HQUZZTJTYYBZNI-UHFFFAOYSA-N [1-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol Chemical compound C=12N=CN(C3(CO)C=CCC3)C2=NC(N)=NC=1NC1CC1 HQUZZTJTYYBZNI-UHFFFAOYSA-N 0.000 claims 1
WJDFLCXFDSYKID-UHFFFAOYSA-N cyclopenten-1-ylmethanol Chemical compound OCC1=CCCC1 WJDFLCXFDSYKID-UHFFFAOYSA-N 0.000 claims 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 62
239000000243 solution Substances 0.000 description 51
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
239000000047 product Substances 0.000 description 27
239000000725 suspension Substances 0.000 description 23
239000013543 active substance Substances 0.000 description 21
238000009472 formulation Methods 0.000 description 20
239000007787 solid Substances 0.000 description 18
239000003826 tablet Substances 0.000 description 18
150000003890 succinate salts Chemical class 0.000 description 16
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 12
239000000843 powder Substances 0.000 description 12
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
229940069328 povidone Drugs 0.000 description 8
239000002253 acid Substances 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
239000003995 emulsifying agent Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
238000001228 spectrum Methods 0.000 description 7
241000725303 Human immunodeficiency virus Species 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000013270 controlled release Methods 0.000 description 6
239000008213 purified water Substances 0.000 description 6
208000030507 AIDS Diseases 0.000 description 5
241000700721 Hepatitis B virus Species 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
150000001298 alcohols Chemical class 0.000 description 5
239000002585 base Substances 0.000 description 5
239000006071 cream Substances 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
235000011187 glycerol Nutrition 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 4
150000001558 benzoic acid derivatives Chemical class 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000004296 chiral HPLC Methods 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
235000008504 concentrate Nutrition 0.000 description 4
238000004821 distillation Methods 0.000 description 4
235000019197 fats Nutrition 0.000 description 4
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
229960001627 lamivudine Drugs 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000005406 washing Methods 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
239000003610 charcoal Substances 0.000 description 3
239000008119 colloidal silica Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000008109 sodium starch glycolate Substances 0.000 description 3
229940079832 sodium starch glycolate Drugs 0.000 description 3
229920003109 sodium starch glycolate Polymers 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
239000000654 additive Substances 0.000 description 2
229960001997 adefovir Drugs 0.000 description 2
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229940082500 cetostearyl alcohol Drugs 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
238000000227 grinding Methods 0.000 description 2
UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
229940080313 sodium starch Drugs 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
WKVDSZYIGHLONN-RRKCRQDMSA-N 5-chloro-1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](F)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Cl)=C1 WKVDSZYIGHLONN-RRKCRQDMSA-N 0.000 description 1
IYWUSKBMXQERLH-UHFFFAOYSA-N 6-n-cyclopropyl-7h-purine-2,6-diamine Chemical compound C=12N=CNC2=NC(N)=NC=1NC1CC1 IYWUSKBMXQERLH-UHFFFAOYSA-N 0.000 description 1
206010001513 AIDS related complex Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
239000004358 Butane-1, 3-diol Substances 0.000 description 1
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000976924 Inca Species 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010033885 Paraparesis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
240000005809 Prunus persica Species 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
229940089206 anhydrous dextrose Drugs 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229940075894 denatured ethanol Drugs 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
229960003804 efavirenz Drugs 0.000 description 1
XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960001936 indinavir Drugs 0.000 description 1
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000012212 insulator Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
229960000884 nelfinavir Drugs 0.000 description 1
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229960000689 nevirapine Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000012958 reprocessing Methods 0.000 description 1
229960000311 ritonavir Drugs 0.000 description 1
NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229960001852 saquinavir Drugs 0.000 description 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229960001203 stavudine Drugs 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Seasonings (AREA)

BG103959A 1997-05-17 1999-12-07 Карбоцикличен нуклеозиден хемисулфат и неговото използване при лечението на вирусни инфекции BG64390B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9709945.1A GB9709945D0 (en)	1997-05-17	1997-05-17	A novel salt
PCT/EP1998/002835 WO1998052949A1 (en)	1997-05-17	1998-05-14	Carbocyclic nucleoside hemisulfate and its use in treating viral infections

Publications (2)

Publication Number	Publication Date
BG103959A BG103959A (en)	2000-12-29
BG64390B1 true BG64390B1 (bg)	2004-12-30

Family

ID=10812407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103959A BG64390B1 (bg)	1997-05-17	1999-12-07	Карбоцикличен нуклеозиден хемисулфат и неговото използване при лечението на вирусни инфекции

Country Status (50)

Country	Link
US (1)	US6294540B1 (et)
EP (1)	EP0983271B1 (et)
JP (2)	JP3150711B2 (et)
KR (1)	KR100521292B1 (et)
CN (2)	CN1150194C (et)
AP (1)	AP2009A (et)
AR (2)	AR015668A1 (et)
AT (1)	ATE259811T1 (et)
AU (1)	AU739953B2 (et)
BG (1)	BG64390B1 (et)
BR (1)	BRPI9809126B8 (et)
CA (1)	CA2289753C (et)
CO (1)	CO4940435A1 (et)
DE (1)	DE69821758T2 (et)
DK (1)	DK0983271T3 (et)
DZ (1)	DZ2493A1 (et)
EA (1)	EA001809B1 (et)
EE (1)	EE03924B1 (et)
EG (1)	EG23836A (et)
ES (1)	ES2214712T3 (et)
GB (3)	GB9709945D0 (et)
GE (1)	GEP20022680B (et)
HN (1)	HN1998000071A (et)
HR (1)	HRP980265B1 (et)
HU (1)	HU226563B1 (et)
ID (1)	ID24910A (et)
IL (2)	IL132793A0 (et)
IS (1)	IS2207B (et)
JO (1)	JO2032B1 (et)
MA (1)	MA26498A1 (et)
MY (1)	MY120151A (et)
NO (1)	NO324731B1 (et)
NZ (2)	NZ500865A (et)
OA (1)	OA11304A (et)
PA (1)	PA8451301A1 (et)
PE (1)	PE78799A1 (et)
PL (1)	PL189527B1 (et)
PT (1)	PT983271E (et)
RS (1)	RS49655B (et)
SA (1)	SA98190179B1 (et)
SI (1)	SI0983271T1 (et)
SK (1)	SK285159B6 (et)
SV (1)	SV1998000057A (et)
TN (1)	TNSN98065A1 (et)
TR (1)	TR199902810T2 (et)
TW (1)	TW480259B (et)
UA (1)	UA56231C2 (et)
UY (1)	UY25004A1 (et)
WO (1)	WO1998052949A1 (et)
ZA (2)	ZA984085B (et)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9802472D0 (en) *	1998-02-06	1998-04-01	Glaxo Group Ltd	Pharmaceutical compositions
HU226998B1 (en) *	2000-11-23	2010-04-28	Richter Gedeon Nyrt	Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
GB0320738D0 (en)	2003-09-04	2003-10-08	Glaxo Group Ltd	Novel process
KR101396686B1 (ko) *	2006-09-28	2014-05-16	에스티브 퀴미카 에스.에이.	아바카비어 조제 방법
EP1905772A1 (en)	2006-09-28	2008-04-02	Esteve Quimica, S.A.	Process for the preparation of abacavir
EP2085397A1 (en)	2008-01-21	2009-08-05	Esteve Quimica, S.A.	Crystalline form of abacavir
EP2218721A1 (en) *	2009-02-11	2010-08-18	LEK Pharmaceuticals d.d.	Novel salts of sitagliptin
EP2305680A3 (en)	2009-09-30	2011-05-18	Aurobindo Pharma Limited	Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
UA105556C2 (uk)	2010-01-27	2014-05-26	Віів Гелскер Компані	Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
CN103282369A (zh)	2011-04-08	2013-09-04	劳乐斯实验室私营有限公司	抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物
JP6391561B2 (ja)	2013-02-27	2018-09-19	国立大学法人京都大学	がんの予防または治療用医薬組成物
CN104788451A (zh) *	2014-01-21	2015-07-22	浙江九洲药业股份有限公司	一种阿巴卡韦的制备方法
CN105315280A (zh) *	2014-06-06	2016-02-10	上海迪赛诺化学制药有限公司	一种阿巴卡韦结晶体及其制备方法
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0434450A2 (en) *	1989-12-22	1991-06-26	The Wellcome Foundation Limited	Therapeutic nucleosides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9417249D0 (en) *	1994-08-26	1994-10-19	Wellcome Found	A novel salt
MY115461A (en) *	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
ATE230267T1 (de)	1996-06-25	2003-01-15	Glaxo Group Ltd	Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv

1997
- 1997-05-17 GB GBGB9709945.1A patent/GB9709945D0/en active Pending
1998
- 1998-04-15 TN TNTNSN98065A patent/TNSN98065A1/fr unknown
- 1998-05-14 CO CO98027044A patent/CO4940435A1/es unknown
- 1998-05-14 JP JP54991098A patent/JP3150711B2/ja not_active Expired - Lifetime
- 1998-05-14 EA EA199900944A patent/EA001809B1/ru not_active IP Right Cessation
- 1998-05-14 NZ NZ500865A patent/NZ500865A/en not_active IP Right Cessation
- 1998-05-14 ZA ZA9804085A patent/ZA984085B/xx unknown
- 1998-05-14 IL IL13279398A patent/IL132793A0/xx active IP Right Grant
- 1998-05-14 AT AT98925601T patent/ATE259811T1/de active
- 1998-05-14 EE EEP199900537A patent/EE03924B1/et unknown
- 1998-05-14 HU HU0002754A patent/HU226563B1/hu unknown
- 1998-05-14 CA CA002289753A patent/CA2289753C/en not_active Expired - Lifetime
- 1998-05-14 PA PA19988451301A patent/PA8451301A1/es unknown
- 1998-05-14 TR TR1999/02810T patent/TR199902810T2/xx unknown
- 1998-05-14 ID IDW991393A patent/ID24910A/id unknown
- 1998-05-14 HN HN1998000071A patent/HN1998000071A/es unknown
- 1998-05-14 PT PT98925601T patent/PT983271E/pt unknown
- 1998-05-14 KR KR10-1999-7010584A patent/KR100521292B1/ko not_active Expired - Lifetime
- 1998-05-14 WO PCT/EP1998/002835 patent/WO1998052949A1/en not_active Ceased
- 1998-05-14 CN CNB988070731A patent/CN1150194C/zh not_active Expired - Lifetime
- 1998-05-14 DE DE1998621758 patent/DE69821758T2/de not_active Expired - Lifetime
- 1998-05-14 EP EP98925601A patent/EP0983271B1/en not_active Expired - Lifetime
- 1998-05-14 DK DK98925601T patent/DK0983271T3/da active
- 1998-05-14 ES ES98925601T patent/ES2214712T3/es not_active Expired - Lifetime
- 1998-05-14 UA UA99116246A patent/UA56231C2/uk unknown
- 1998-05-14 EG EG52698A patent/EG23836A/xx active
- 1998-05-14 US US09/423,982 patent/US6294540B1/en not_active Expired - Lifetime
- 1998-05-14 AU AU77655/98A patent/AU739953B2/en not_active Expired
- 1998-05-14 AP APAP/P/1999/001688A patent/AP2009A/en active
- 1998-05-14 MY MYPI98002147A patent/MY120151A/en unknown
- 1998-05-14 AR ARP980102251A patent/AR015668A1/es active IP Right Grant
- 1998-05-14 GB GB9926839A patent/GB2340491B/en not_active Expired - Lifetime
- 1998-05-14 GE GEAP19985087A patent/GEP20022680B/en unknown
- 1998-05-14 GB GB0010222A patent/GB2348202B/en not_active Expired - Lifetime
- 1998-05-14 NZ NZ510622A patent/NZ510622A/en not_active IP Right Cessation
- 1998-05-14 RS YUP-595/99A patent/RS49655B/sr unknown
- 1998-05-14 CN CNB031029213A patent/CN100408580C/zh not_active Expired - Lifetime
- 1998-05-14 BR BRPI9809126A patent/BRPI9809126B8/pt not_active IP Right Cessation
- 1998-05-14 ZA ZA9804083A patent/ZA984083B/xx unknown
- 1998-05-14 PE PE1998000374A patent/PE78799A1/es not_active IP Right Cessation
- 1998-05-14 SI SI9830615T patent/SI0983271T1/xx unknown
- 1998-05-14 PL PL98336888A patent/PL189527B1/pl unknown
- 1998-05-14 SK SK1561-99A patent/SK285159B6/sk not_active IP Right Cessation
- 1998-05-15 TW TW087107544A patent/TW480259B/zh not_active IP Right Cessation
- 1998-05-15 HR HR980265A patent/HRP980265B1/xx not_active IP Right Cessation
- 1998-05-15 SV SV1998000057A patent/SV1998000057A/es active IP Right Grant
- 1998-05-15 UY UY25004A patent/UY25004A1/es not_active IP Right Cessation
- 1998-05-16 JO JO19982032A patent/JO2032B1/en active
- 1998-05-17 DZ DZ980103A patent/DZ2493A1/xx active
- 1998-06-21 SA SA98190179A patent/SA98190179B1/ar unknown
1999
- 1999-11-08 IL IL132793A patent/IL132793A/en not_active IP Right Cessation
- 1999-11-11 IS IS5246A patent/IS2207B/is unknown
- 1999-11-16 OA OA9900249A patent/OA11304A/en unknown
- 1999-11-16 NO NO19995622A patent/NO324731B1/no not_active IP Right Cessation
- 1999-12-07 BG BG103959A patent/BG64390B1/bg unknown
2000
- 2000-03-07 MA MA25078A patent/MA26498A1/fr unknown
- 2000-05-11 JP JP2000138178A patent/JP2000327679A/ja active Pending
2007
- 2007-01-02 AR ARP070100006A patent/AR059120A2/es active IP Right Grant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0434450A2 (en) *	1989-12-22	1991-06-26	The Wellcome Foundation Limited	Therapeutic nucleosides

Also Published As

Publication number	Publication date
BRPI9809126B1 (pt)	2018-02-06
CA2289753C (en)	2007-01-23
HRP980265B1 (en)	2004-10-31
EP0983271A1 (en)	2000-03-08
NO995622D0 (no)	1999-11-16
KR100521292B1 (ko)	2005-10-17
TNSN98065A1 (fr)	2005-03-15
GB9709945D0 (en)	1997-07-09
PT983271E (pt)	2004-07-30
EE03924B1 (et)	2002-12-16
US6294540B1 (en)	2001-09-25
CN1515572A (zh)	2004-07-28
GEP20022680B (en)	2002-04-25
GB2340491A (en)	2000-02-23
IS2207B (is)	2007-02-15
HN1998000071A (es)	1999-03-19
AU7765598A (en)	1998-12-11
AP2009A (en)	2009-06-26
PA8451301A1 (es)	2000-05-24
CN100408580C (zh)	2008-08-06
TW480259B (en)	2002-03-21
EE9900537A (et)	2000-06-15
PL336888A1 (en)	2000-07-17
GB0010222D0 (en)	2000-06-14
SI0983271T1 (en)	2004-06-30
JP2000327679A (ja)	2000-11-28
NZ500865A (en)	2001-04-27
DK0983271T3 (da)	2004-05-10
AR059120A2 (es)	2008-03-12
SA98190179B1 (ar)	2006-08-15
MA26498A1 (fr)	2004-12-20
GB2348202B (en)	2001-08-08
CO4940435A1 (es)	2000-07-24
JP3150711B2 (ja)	2001-03-26
NO324731B1 (no)	2007-12-03
BRPI9809126B8 (pt)	2021-07-06
ZA984085B (en)	2000-01-26
TR199902810T2 (xx)	2000-02-21
HUP0002754A2 (hu)	2001-06-28
ZA984083B (en)	1999-11-15
UY25004A1 (es)	2000-10-31
EG23836A (en)	2007-10-02
JP2000514096A (ja)	2000-10-24
MY120151A (en)	2005-09-30
YU59599A (et)	2002-08-12
BR9809126A (pt)	2000-08-01
SK156199A3 (en)	2000-07-11
EA199900944A1 (ru)	2000-06-26
BG103959A (en)	2000-12-29
AR015668A1 (es)	2001-05-16
CN1263529A (zh)	2000-08-16
ID24910A (id)	2000-08-31
JO2032B1 (en)	1999-05-15
CA2289753A1 (en)	1998-11-26
EP0983271B1 (en)	2004-02-18
IL132793A0 (en)	2001-03-19
GB9926839D0 (en)	2000-01-12
PL189527B1 (pl)	2005-08-31
HUP0002754A3 (en)	2003-01-28
PE78799A1 (es)	1999-08-31
RS49655B (sr)	2007-09-21
AU739953B2 (en)	2001-10-25
GB2348202A (en)	2000-09-27
OA11304A (en)	2003-10-22
SK285159B6 (sk)	2006-07-07
KR20010012623A (ko)	2001-02-26
WO1998052949A1 (en)	1998-11-26
ATE259811T1 (de)	2004-03-15
ES2214712T3 (es)	2004-09-16
DE69821758T2 (de)	2005-01-13
EA001809B1 (ru)	2001-08-27
IL132793A (en)	2006-10-31
HK1024236A1 (en)	2000-10-05
DE69821758D1 (de)	2004-03-25
NO995622L (no)	2000-01-14
HRP980265A2 (en)	1999-02-28
SV1998000057A (es)	1999-03-02
NZ510622A (en)	2002-04-26
GB2340491B (en)	2000-10-18
CN1150194C (zh)	2004-05-19
UA56231C2 (uk)	2003-05-15
IS5246A (is)	1999-11-11
HU226563B1 (en)	2009-04-28
DZ2493A1 (fr)	2004-06-20
AP9901688A0 (en)	1999-12-31

Publication	Publication Date	Title
RS59599B1 (sr)	2020-01-31	Formulacije tableta neratinib maleata
BG65837B1 (bg)	2010-02-26	Кристални и аморфна форми на триазоло (4,5-d) пиримидин
US6294540B1 (en)	2001-09-25	Carbocyclic nucleoside hemisulfate and its use in treating viral infections
RU2145324C1 (ru)	2000-02-10	Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2-циклопентен-1-метанола в качестве противовирусного агента
JP2010505747A (ja)	2010-02-25	Ａ２ａアデノシンレセプタの選択的アンタゴニスト
JP7305658B2 (ja)	2023-07-10	抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン
KR100889427B1 (ko)	2009-03-23	선택적 ｃｏｘ-2 억제제로서 유용한 피리미딘 유도체
AU769660B2 (en)	2004-01-29	Carbocyclic nucleoside hemisulfate and its use in treating viral infections
CZ406899A3 (cs)	2000-04-12	Hemisulfát (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanolu
MXPA99010373A (en)	2000-09-04	Carbocyclic nucleoside hemisulfate and its use in treating viral infections
HK1024236B (en)	2004-09-24	Carbocyclic nucleoside hemisulfate and its use in treating viral infections
NO854392L (no)	1986-05-06	Fremgangsmaate ved fremstilling av 3-amino-2,3-dihydro-1-benzoxepin-derivater.
JPH03127733A (ja)	1991-05-30	ベンゾイソオキサゾリン―３―オン誘導体を含有する抗うつ剤